Statins:: new therapeutic possibilities for osteoporosis?

被引：1

作者：

Laufs, U ^{[1
]}

Werner, N ^{[1
]}

Böhm, M ^{[1
]}

Nickenig, G ^{[1
]}

机构：

[1] Univ Saarlandes Kliniken, Med Klin & Poliklin, D-66421 Homburg, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2001年 / 126卷 / 19期

关键词：

D O I：

10.1055/s-2001-13809

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：565 / 568

页数：4

共 24 条

[1] Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates:: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs [J].

Benford, HL ;

Frith, JC ;

Auriola, S ;

Mönkkönen, J ;

Rogers, MJ .

MOLECULAR PHARMACOLOGY, 1999, 56 (01) :131-140

[2] Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase [J].

Bergstrom, JD ;

Bostedor, RG ;

Masarachia, PJ ;

Reszka, AA ;

Rodan, G .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 373 (01) :231-241

[3] Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women [J].

Chan, KA ;

Andrade, SE ;

Boles, M ;

Buist, DSM ;

Chase, GA ;

Donahue, JG ;

Goodman, MJ ;

Gurwitz, JH ;

LaCroix, AZ ;

Platt, R .

LANCET, 2000, 355 (9222) :2185-2188

[4] A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].

Chesnut, CH ;

Silverman, S ;

Andriano, K ;

Genant, H ;

Gimona, A ;

Harris, S ;

Kiel, D ;

LeBoff, M ;

Maricic, M ;

Miller, P ;

Moniz, C ;

Peacock, M ;

Richardson, P ;

Watts, N ;

Baylink, D .

AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276

[5] Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298 [J].

Coxon, FP ;

Helfrich, MH ;

Van't Hof, R ;

Sebti, S ;

Ralston, SH ;

Hamilton, A ;

Rogers, MJ .

JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (08) :1467-1476

[6] Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [J].

Delmas, PD ;

Bjarnason, NH ;

Mitlak, BH ;

Ravoux, AC ;

Shah, AS ;

Huster, WJ ;

Draper, M ;

Christiansen, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (23) :1641-1647

[7] Treatment of postmenopausal osteoporosis [J].

Eastell, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (11) :736-746

[8] Oral statins and increased bone-mineral density in postmenopausal women [J].

Edwards, CJ ;

Hart, DJ ;

Spector, TD .

LANCET, 2000, 355 (9222) :2218-2219

[9] THE EFFECT OF POSTMENOPAUSAL ESTROGEN THERAPY ON BONE-DENSITY IN ELDERLY WOMEN [J].

FELSON, DT ;

ZHANG, YQ ;

HANNAN, MT ;

KIEL, DP ;

WILSON, PWF ;

ANDERSON, JJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (16) :1141-1146

[10] Alendronate mechanism of action:: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro [J].

Fisher, JE ;

Rogers, MJ ;

Halasy, JM ;

Luckman, SP ;

Hughes, DE ;

Masarachia, PJ ;

Wesolowski, G ;

Russell, RGG ;

Rodan, GA ;

Reszka, AA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) :133-138

← 1 2 3 →